ACCESS HD: Comparing Catheters to Fistulas in Elderly Patients Starting Hemodialysis (ACCESS HD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02675569|
Recruitment Status : Recruiting
First Posted : February 5, 2016
Last Update Posted : July 21, 2022
|Condition or disease||Intervention/treatment||Phase|
|End-stage Kidney Failure||Procedure: Catheter Procedure: Fistula||Not Applicable|
Purpose: This vanguard phase of the RCT will help to address challenges related to patient recruitment, protocol adherence, safety, and data collection in the hemodialysis population. The primary outcome for this vanguard phase of the RCT is feasibility, which will be measured by patient recruitment and protocol adherence. The secondary outcomes include feasibility-related outcomes, safety (which will include expected procedure-related outcomes and causes for hospital admissions), and other protocol violations.
Hypothesis: Results obtained from the vanguard phase of the RCT will provide feasibility and safety data for conducting a large RCT, which will establish a better understanding of the clinical outcomes associated with the use of fistula versus catheter for vascular access in the hemodialysis population.
Research Method: This is a multicenter, open-label, RCT, and is expected to be conducted over 24 months. All consented and enrolled participants who meet the eligibility criteria will have the following data collected in a minimal dataset: eligibility, age, sex, program/center, height, weight, comorbid conditions, and details of any prior treatment for acute or chronic kidney failure (e.g., previous peritoneal dialysis, kidney transplant, or hemodialysis). The following additional data will be collected at baseline: baseline laboratory values, baseline hemodialysis initiation, history of access procedures, and patient-reported outcome measures (includes data on quality of life and a vascular access questionnaire). The vanguard phase of the RCT will consist of 6 months of site preparation, approximately 24 months of participant accrual, and 6 months of additional follow-up time for the last randomized participant. An additional 6 months will be used to assess the preliminary data, prepare the report of this vanguard phase of the RCT, and to prepare and submit funding applications for the large RCT. Participants in the vanguard phase of the RCT will be rolled into the large RCT, and will therefore be followed for a total of 24 months (2 years) in Canada and a total of 36 months (3 years) in Australia after randomization to assess adherence to the trial protocol, assess safety outcomes, and collect qualitative data.
Statistical Analysis Plan: The primary analysis of the vanguard phase of the RCT will be descriptive. The proportion of people meeting each of the feasibility endpoints with accompanying 95% confidence intervals will be calculated. Investigators will describe participant characteristics and evaluate reasons for protocol violation, as well as calculate rates of drop-ins and other events. Interim or subgroup analyses will not be conducted in this vanguard phase of the RCT.
Expected Procedure-Related Outcomes (Safety Data): As both catheter and fistula treatment strategies are standard of care, the procedure-related outcomes are well known. Investigators will collect only expected procedure-related outcomes (i.e., events that have a potentially causal relationship to the strategy) that occur within 7 days of the execution of any access related intervention. These will include hospital admissions and prolongation of hospitalization, status changes, bacterial infections, catheter or exit site infections, cannulation injury events. In addition, sites will report all incidents of participant death that occur during the trial period. Cause of death will be determined by trial site investigators, based on a trial-specific list of classifications, and will be adjudicated for accuracy by appropriate members of the trial steering committee, who will be blinded to treatment arm.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||ACCESS HD Pilot: A Randomized Trial Comparing Catheters to Fistulas in Elderly patientS Starting HemoDialysis|
|Actual Study Start Date :||May 2016|
|Estimated Primary Completion Date :||March 2025|
|Estimated Study Completion Date :||March 2025|
Active Comparator: Catheter
Catheter is a method of vascular access for hemodialysis. It consists of a long, thin plastic tube and may be either tunnelled or non-tunnelled.
A method of vascular access for hemodialysis that all participants will have in place prior to randomization.
Fistula is a type of vascular access strategy for hemodialysis in which a direct connection of an artery to a vein is created. It is intended to provide an access with good blood flow that can last for decades.
A type of vascular access strategy for hemodialysis which involves connecting the artery and the veins in the participant's arm.
- Feasibility; proportion of eligible people who are randomized (at least 25%) [ Time Frame: 42 months ]
- Feasibility; proportion of those randomized to the intervention arm receiving a fistula attempt within 90 days of randomization (at least 80%) [ Time Frame: 42 months ]
- Descriptive; reasons for exclusion of all screened participants (feasibility) [ Time Frame: 42 months ]Investigators will consider the reasons for exclusion of screened participants (including competing studies).
- Descriptive; reasons that people decline to participate (feasibility) [ Time Frame: 42 months ]Investigators will consider the reasons that people decline to participate.
- Descriptive; reasons people are considered ineligible for a fistula attempt (feasibility) [ Time Frame: 42 months ]Investigators will consider the reasons that people are considered ineligible for a fistula attempt.
- Descriptive; reasons for delayed access to fistula surgery (feasibility) [ Time Frame: 42 months ]Investigators will consider the reasons for delayed access to fistula surgery (> 90 days from randomization).
- Safety; expected procedure-related outcomes for both catheter and fistula treatment strategies that occur within 7 days of the execution of any access related intervention [ Time Frame: 7 days ]Investigators will collect information on expected procedure-related outcomes for both catheter and fistula treatment strategies that occur within 7 days of the execution of any access related intervention. Additionally, coordinators will track causes for hospital admissions and prolongation of hospitalization, and sites will report all incidents of participant death that occur during the trial period to identify if outcomes may have resulted from the trial procedures.
- Number of drop-ins [ Time Frame: 42 months ]Investigators will collect the number and reasons for drop-ins and drop-outs.
- Number of drop-outs [ Time Frame: 42 months ]Investigators will collect the number and reasons for drop-ins and drop-outs.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02675569
|Contact: Sorcha Mulligan||416-360-4000 ext firstname.lastname@example.org|
|Contact: Sharon Gulewich||403-955-6387||Sharon.Gulewich@albertahealthservices.ca|
|Australia, Australian Capital Territory|
|The Canberra Hospital||Not yet recruiting|
|Garran, Australian Capital Territory, Australia, 2605|
|Contact: Girish Talaulikar 61251242821 email@example.com|
|Principal Investigator: Girish Talaulikar|
|Australia, New South Wales|
|Illawarra Shoalhaven Local Health District (ISLHD)||Recruiting|
|Wollongong, New South Wales, Australia, 2500|
|Contact: Hicham Hassan 61242275443 HichamIbrahim.CheikhHassan@health.nsw.gov.au|
|Principal Investigator: Hicham Hassan|
|Sunshine Coast Hospital and Health Service (SCHHS)||Recruiting|
|Birtinya, Queensland, Australia, 4575|
|Contact: Nicholas Gray 6175025876 firstname.lastname@example.org|
|Principal Investigator: Nicholas Gray|
|University of Calgary||Recruiting|
|Calgary, Alberta, Canada, T2R 0X7|
|Contact: Rob Quinn email@example.com|
|Contact: Sharon Gulewich Sharon.Gulewich@albertahealthservices.ca|
|Principal Investigator: Rob Quinn|
|Principal Investigator: Pietro Ravani|
|University of Alberta||Active, not recruiting|
|Edmonton, Alberta, Canada, T6G 2G3|
|University of Manitoba||Completed|
|Winnipeg, Manitoba, Canada, R3A 1R9|
|Canada, Newfoundland and Labrador|
|Memorial University of Newfoundland||Completed|
|St. John's, Newfoundland and Labrador, Canada, A1B 3V6|
|St. Joseph's Hospital||Withdrawn|
|Hamilton, Ontario, Canada, L8N 4A6|
|London Health Sciences Centre||Withdrawn|
|London, Ontario, Canada, N6A 5W9|
|The Ottawa Hospital||Recruiting|
|Ottawa, Ontario, Canada, K1H 7W9|
|Contact: Swapnil Hiremath 613-738-8400 ext 82762 firstname.lastname@example.org|
|Contact: Jennifer Biggs email@example.com|
|Principal Investigator: Swapnil Hiremath|
|Humber River Hospital||Completed|
|Toronto, Ontario, Canada, M3M 0B2|
|Sunnybrook Health Sciences Centre||Recruiting|
|Toronto, Ontario, Canada, M4N 3M5|
|Contact: Matthew Oliver 416-480-6100 ext 7061 firstname.lastname@example.org|
|Contact: Amina Mahmood 416-480-6100 ext 1291 email@example.com|
|Principal Investigator: Matthew Oliver|
|St. Michael's Hospital||Recruiting|
|Toronto, Ontario, Canada, M5B 1W8|
|Contact: Ron Wald 416-867-3703 firstname.lastname@example.org|
|Contact: Ivana Prce email@example.com|
|Principal Investigator: Ron Wald|
|Principal Investigator:||Rob Quinn, PhD||University of Calgary|
|Principal Investigator:||Pietro Ravani, PhD||University of Calgary|